Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344209 | 0.87 | NPC1 (1.00) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL31411480 | 0.87 | NPC1 (1.00) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL1270302 | 0.83 | RAB9A (0.69) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL6857852 | 0.82 | NPC1 (0.88) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL3723177 | 0.82 | RAB9A (0.80) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL30852954 | 0.82 | RAB9A (0.80) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL10780666 | 0.80 | NPC1 (0.65) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL25356036 | 0.80 | NPC1 (0.77) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL959541 | 0.80 | NPC1 (0.77) | NPC1RAB9AHPGDALDH1A1POLB | |
| SCHEMBL8006309 | 0.80 | NPC1 (0.77) | NPC1RAB9AHPGDALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116751151-B | One-pot method for preparing 5-chloro-7-methyl isatin | 瑞弘(天津)科技有限公司 | 2025-10-10 | — | — | CN | disclosed |
| US-7276511-B2 | Benzylamine derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20060194841-A1 | E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1650189-A1 | BENZYLAMINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-6117885-A | Biphenyl-substituted quinoline derivatives | E. R. SQUIBB & SONS, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0556060-A1 | Biphenyl-substituted quinoline and naphthyridines derivatives as angiotensine II antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194841-A1 | E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; irritable bowel syndrome, pain, anxiety, COPD, headaches and vomiting | KCNAB1, BDKRB2, ARRB1 | NPC1 386/4885RAB9A 1811/4885HPGD 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.